What is ALS Phase 3 Study Ceftriaxone?
CATEGORY:
NCT00349622 is a clinical trial with ceftriaxone in subjects with amyotrophic lateral sclerosis (ALS). Other study IDs include: U01NS049640-02, NINDS, U01NS049640-02, NINDS CRC.
Save up to 80% off your prescriptions!
How do members experience ALS Phase 3 Study Ceftriaxone?
Top 5 reported purposes & perceived effectiveness
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Amyotrophic lateral sclerosis | 13 | 24 | |
| Participate in clinical trial | 10 | 12 |
Common side effects
| Side effect | Patients | Percentage |
|---|---|---|
| Gallstones | 3 | |
| Acid reflux | 1 | |
| Candida (fungal) infection | 1 | |
| Diarrhea | 1 | |
| Fever | 1 | |
| Flank pain | 1 |
Side effect severity
| Severity | Evaluations | Percentage |
|---|---|---|
| Severe | 2 | |
| Moderate | 11 | |
| Mild | 6 | |
| None | 15 |
Member evaluations
7
7573
evaluated on Apr 29, 2011
- Perceived effectiveness for amyotrophic lateral sclerosis: Can't tell
- Side effects: None
moolaw
evaluated on Dec 20, 2010
- Perceived effectiveness for Participate in clinical trial: Can't tell
- Side effects: Mild
Learn more about our community’s experience with ALS Phase 3 Study Ceftriaxone
What are people saying about ALS Phase 3 Study Ceftriaxone?
27
27
members have reported taking ALS Phase 3 Study Ceftriaxone
Join the conversation and connect with people who have taken ALS Phase 3 Study Ceftriaxone
Last updated: